Form 8-K · Current Report · Filed 2025-04-30
Ionis Pharmaceuticals Reports Q1 2025 Financial Results
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2025, showing a 10% increase in revenue to $132 million, driven by higher commercial revenue from the launch of TRYNGOLZA and increased royalty revenue. The company also raised its 2025 financial guidance, anticipating a stronger performance across its portfolio of marketed medicines and pipeline drugs. Ionis generated $6 million in net product sales from TRYNGOLZA in its first full quarter and is on track for additional launches this year.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-25-016562
- CIK
- 0000874015
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$29.81
Next session
+6.4%
Since filing
+73.7%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Exhibits (1)
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.